Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer-Reference-Cited by-同舟云学术

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Published:2010-12-21 Issue:2 Volume:54 Page:635-654
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pierre Fabrice¹,Chua Peter C.¹,O’Brien Sean E.¹,Siddiqui-Jain Adam¹,Bourbon Pauline¹,Haddach Mustapha¹,Michaux Jerome¹,Nagasawa Johnny¹,Schwaebe Michael K.¹,Stefan Eric¹,Vialettes Anne¹,Whitten Jeffrey P.¹,Chen Ta Kung¹,Darjania Levan¹,Stansfield Ryan¹,Anderes Kenna¹,Bliesath Josh¹,Drygin Denis¹,Ho Caroline¹,Omori May¹,Proffitt Chris¹,Streiner Nicole¹,Trent Katy¹,Rice William G.¹,Ryckman David M.¹

Affiliation:

1. Cylene Pharmaceuticals, 5820 Nancy Ridge Drive, Suite 200, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm101251q

Reference62 articles.

1. Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2

2. One‐thousand‐and‐one substrates of protein kinase CK2?

3. Protein kinase CK2: a newcomer in the ‘druggable kinome’